+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating ARO-ALK7, a drug given by injection, in adult participants with obesity, both with and without Type 2 Diabetes Mellitus T2DM. This Phase 12a study aims to understand the safety, tolerability, how the body processes the drug, and how the drug affects the body. The study is divided into two parts Part 1 focuses on adults with obesity without T2DM, and Part 2 includes adults with obesity both with and without T2DM, testing ARO-ALK7 alone or combined with tirzepatide. Participants receive either single or multiple doses of ARO-ALK7 or matching placebo injections. In Part 2, some participants also receive weekly tirzepatide starting from Day 15 through Day 253. The doses of ARO-ALK7 are escalated to explore different levels of the drug. The study compares ARO-ALK7 alone, placebo, ARO-ALK7 combined with tirzepatide, and placebo combined with tirzepatide to assess their effects. During the study, participants are monitored for treatment-emergent adverse events until Day 253. Researchers collect detailed information on how the drug moves and acts in the body, especially during Part 1. Participants will have scheduled visits to receive treatments and undergo safety and effectiveness assessments. The total study duration covers up to about 8 and a half months, including dosing and follow-up, to fully evaluate the drugs impact and safety profile.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
8 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a single injection of PTP-001 MOTYS in treating knee osteoarthritis OA in adults aged 40 to 80 years. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial compares PTP-001 to a placebo over a 52-week period in participants with mild to moderate knee OA confirmed by X-ray and symptoms. The goal is to assess improvements in knee function and pain over time. Participants will be randomly assigned to receive either a single 200 mg injection of PTP-001 or a placebo injection directly into the affected knee on Day 1. The study includes a screening period of up to 28 days before treatment, followed by the injection day and a 12-month follow-up phase to monitor outcomes. At least 260 participants will take part, split evenly between the two groups. Throughout the study, participants will attend scheduled visits for assessments including knee pain and function questionnaires, such as the WOMAC and PGA-OA scores, at 6, 9, and 12 months. Researchers will track improvements in knee symptoms and overall osteoarthritis status, as well as monitor safety and tolerability. Participants are expected to comply with study visits and restrictions, using only acetaminophen as needed for pain relief during the trial.

Age: 40Years - 80YearsAll GendersPhase 3
18 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety of IGT-303, a drug given either under the skin or into a vein, in healthy volunteers and people with chronic kidney disease caused by type 2 diabetic nephropathy. The study aims to find out if IGT-303 is safe when given as a single dose or multiple doses compared to a placebo. This is a randomized, double-blind, placebo-controlled clinical trial conducted in multiple centers. Participants will be assigned to receive either IGT-303 or a placebo normal saline through intravenous or subcutaneous administration. The study has two parts Part A involves single ascending doses across six groups, and Part B involves multiple ascending doses across three groups. Researchers will monitor participants closely throughout the study period, which includes dosing and follow-up. During the study, participants will be assessed for adverse events and treatment-emergent events from screening until day 84. Researchers will also collect pharmacokinetic data to understand how the drug behaves in the body over time. Participants may need to stay overnight at the research site and will be monitored for safety and tolerability during this period. The total study duration extends to approximately 84 days of observation after dosing.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
13 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
S

Actively Recruiting

Researchers are evaluating GRWD0715, an oral drug that selectively inhibits the Endoplasmic Reticulum Aminopeptidase 1 ERAP1 enzyme, as a potential new treatment for axial spondyloarthritis axSpA. AxSpA is a chronic condition caused by inflammation mainly affecting the sacroiliac joints and spine. The study explores whether blocking ERAP1 can stop the immune system from attacking these areas by preventing the creation of a specific self-peptide that triggers inflammation. The study includes four parts Part A involves healthy volunteers receiving a single dose of GRWD0715. Part B includes participants with axSpA who receive the drug daily for 28 days. Part C is an open-label safety phase for participants from previous parts who receive GRWD0715 daily for 8 to 12 weeks. Part D is a randomized phase where participants with axSpA receive either one or two doses of GRWD0715 or a placebo daily for up to 12 weeks. Participants will undergo regular assessments including clinical evaluations based on the Assessment of SpondyloArthritis International Society ASAS core outcome set and MRI scans of the sacroiliac joints and spine. Safety is closely monitored through tracking adverse events and dose-limiting events. Blood samples will be collected to analyze how the drug is processed in the body. The total duration of participation varies by study part, with follow-ups extending up to 12 weeks or more depending on the phase.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
16 locations
P

Actively Recruiting

Researchers are evaluating the preliminary efficacy, safety, and population pharmacokinetics PopPK of ABP-745 in adults aged 18 to 75 years who have atherosclerotic cardiovascular disease ASCVD. This randomized, double-blind, placebo-controlled Phase II study aims to compare the ability of ABP-745 to reduce atherosclerotic plaque against a placebo. The primary measurement of efficacy will be the change in percent atheroma volume PAV after 52 weeks of treatment. Participants will be randomly assigned to one of four groups placebo or one of three different doses of ABP-745 tablets taken orally once daily. Throughout the study, existing lipid-lowering maintenance medications will remain unchanged. The study includes a 52-week treatment period, after which the primary outcome will be assessed. Safety and tolerability will also be monitored up to 14 days after the last dose. During the study, participants will continue their current oral lipid-lowering therapy and attend regular visits for assessments including physical exams, vital signs, laboratory tests, and ECGs. Researchers will measure changes in atherosclerotic plaque volume and monitor for adverse events. The total duration of participation includes the 52-week treatment period plus safety follow-up, with detailed monitoring to evaluate the impact and safety of ABP-745 in this population.

Age: 18Years - 75YearsAll GendersPhase 2
33 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety of two different doses of a Chlamydia mRNA vaccine candidate in adults. The study includes participants aged 18 to 29 years who do not have prior exposure to Chlamydia trachomatis, and those aged 18 to 44 years who are seropositive. The study aims to assess safety and possibly detect early immune responses to the vaccine. Participants are divided into two groups receiving either the first or second dose of the vaccine, or a placebo, given as three intramuscular injections. There are separate cohorts based on Chlamydia trachomatis serostatus. The study lasts about 18 months for each participant, including a 12-month follow-up after the last injection. During the study, participants will be monitored for immediate reactions after injections, injection site and systemic symptoms in the days following, and any adverse events for up to a year after vaccination. Laboratory tests will also be performed to check for abnormal results. Researchers will assess all serious adverse events throughout the study to evaluate safety comprehensively.

Age: 18Years - 44YearsAll GendersPhase 1
7 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of HB-1 compared to a placebo in adults aged 18 to 65 years diagnosed with Post-Traumatic Stress Disorder PTSD. This phase 2, multi-center, randomized, double-blind, placebo-controlled trial will include approximately 200 to 500 participants without severe neuropsychiatric or medical conditions. The study aims to better understand how HB-1 affects PTSD symptoms using established clinical assessments. Participants will receive HB-1, a dual active pharmaceutical ingredient tablet containing telmisartan and verapamil extended release, or a matching placebo. They will start with a lower dose of HB-1 taken once daily and may have their dose increased at Week 4 or Week 8 if symptoms have not sufficiently improved and no serious side effects have occurred. Treatment will continue for 12 weeks, followed by a safety follow-up one week after the last dose. Throughout the study, participants will attend visits at baseline, Week 4, Week 8, and Week 12 for symptom assessments using several clinical scales and questionnaires. Safety monitoring will include checking for adverse events, vital signs, ECGs, and lab tests. The primary outcome is the change in clinician-rated PTSD symptoms. The total participation time is about 13 weeks including treatment and follow-up.

Age: 18Years - 65YearsAll GendersPhase 2
16 locations
P

Actively Recruiting

Researchers are evaluating ARO-DIMERPA, a drug given by injection, in adults with mixed hyperlipidemia to study its safety, how the body processes it, and its effects on cholesterol and triglyceride levels. This study is a Phase 12a, double-blind, placebo-controlled trial designed to test single and multiple doses of ARO-DIMERPA compared to placebo in adult participants. Participants will receive either single or multiple escalating doses of ARO-DIMERPA or a matching placebo given by subcutaneous injection. The study uses a randomized, sequential design with quadruple masking to compare the effects of the drug and placebo. Treatment and monitoring will occur over a period extending up to 36 weeks. During the study, participants will be monitored for treatment-emergent side effects, and their cholesterol and triglyceride levels will be measured at baseline and throughout the 36 weeks. Researchers will also assess the drugs pharmacokinetics over 24 hours after dosing. Participants will have regular visits for evaluations, including blood tests to track safety and drug effects, with the study continuing until July 2027.

Age: 18Years +All GendersPhase 1Phase 2
19 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of different vaccine formulations targeting the Respiratory Syncytial Virus RSV monovalent antigen and the Influenza AH5N1 hemagglutinin subtype 5 H5 antigen in healthy adults aged 18 to 49 years. This phase 1 study aims to understand how well these vaccines work and how safe they are for this age group, with participation durations varying by treatment group and study stage. Participants receive vaccines through intramuscular injections. For certain groups, injections are given on day 1 and day 22 with the H5 Flu vaccines, while others receive a single injection on day 1 with the RSV vaccines. The study is divided into two stages, with Stage 1 lasting approximately 6 to 7 months depending on the arm, and Stage 2 lasting about 7 months for all arms. Vaccines are given according to a randomization schedule across multiple experimental arms. Throughout the study, participants will be monitored closely for side effects such as injection site reactions, systemic symptoms, and any adverse events up to 6 months after vaccination. Researchers will collect blood samples to measure antibody responses before and after vaccination at various time points. The study includes detailed safety assessments, including biological tests and documentation of any serious adverse events or events leading to discontinuation. Participants immune responses to both RSV and Flu H5 antigens will be measured using specific antibody tests over the course of the study.

Age: 18Years - 49YearsAll GendersPhase 1
6 locations

1-10 of 11

1